A Phase 3, Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males, 16 to 26 Years of Age
Latest Information Update: 24 Jul 2024
At a glance
- Drugs V 503 (Primary)
- Indications Human polyomavirus infections
- Focus Adverse reactions; Registrational
- Sponsors Merck Sharp & Dohme Corp.
- 22 Jul 2024 Planned End Date changed from 30 Jan 2025 to 15 Aug 2025.
- 06 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 02 Dec 2020 Status changed from not yet recruiting to recruiting.